# Trait Track Reconciliation Report

## Overview

- Total traits: 696
- All 696 traits assigned exactly once: YES
- Duplicate assignments: 0

## Count per Final Track

| Final Track | Count |
|-------------|-------|
| non_medical_mvp_candidate | 107 |
| medical_sensitive_review | 535 |
| weak_behavioral_or_low_evidence | 30 |
| no_snp_or_not_testable | 24 |
| unclear_manual_review | 0 |
| **Total** | **696** |

## Assignment Verification

- Total traits in commercial catalog: 696
- Total traits in reconciliation table: 696
- All traits assigned exactly once: YES

## Traits Missing from Both MVP and Medical Catalogs

None. All traits are accounted for in either the MVP candidate list, medical catalog, or other tracks.

## Contradictions Between TierA_review and Medical Catalog

None. No contradictions found between QC review and medical catalog.

## Recommended Next Actions per Final Track

### 1. non_medical_mvp_candidate

**Count: 107**

These traits passed QC as safe, non-medical MVP candidates.

**Next actions:**
1. Perform external annotation (dbSNP/Ensembl) for all rsIDs.
2. Conduct GWAS Catalog review for trait-SNP association strength.
3. Validate gene symbols against HGNC.
4. After validation, these traits may become consumer-facing with appropriate disclaimers.
5. Consumer-friendly names must use probabilistic language.

### 2. medical_sensitive_review

**Count: 535**

These traits are medical/sensitive and require clinical, regulatory, and ethical review.

**Next actions:**
1. Perform external annotation (dbSNP/Ensembl/ClinVar/gnomAD/GWAS/PharmGKB).
2. Conduct ClinVar review for clinical significance.
3. Conduct GWAS Catalog review for disease associations.
4. For pharmacogenomics traits, conduct PharmGKB/CPIC review.
5. Establish genetic counseling and consent protocols.
6. Obtain regulatory approval before any reporting.
7. **Not customer-facing.** Requires clinician oversight.

### 3. weak_behavioral_or_low_evidence

**Count: 30**

These traits are based on weak behavioral or personality genetics and are not recommended for commercial use.

**Next actions:**
1. Perform external annotation to validate rsIDs.
2. Conduct GWAS Catalog review — most will likely have weak or non-replicated associations.
3. Conduct ethical review for behavioral genetics reporting.
4. **Not recommended for commercial reporting** unless strong evidence emerges.
5. If reported, must include explicit 'weak evidence' disclaimer.

### 4. no_snp_or_not_testable

**Count: 24**

These traits have no rsIDs linked and cannot be tested with genetic markers.

**Next actions:**
1. Review whether rsIDs can be found from external sources.
2. Some traits (e.g., ancestry) may not require SNP markers.
3. **Not suitable for genetic trait reporting.**
4. Manual review to determine if alternative testing methods exist.

### 5. unclear_manual_review

**Count: 0**

These traits could not be automatically classified and require manual review.

**Next actions:**
1. Manual scientific review to determine appropriate track.
2. Check for data quality issues.
3. Assign to one of the other four tracks after review.
4. **Not customer-facing** until manually reviewed.

## Summary Table

| Final Track | Count | Customer-Facing | External Annotation | Manual Review |
|-------------|-------|-----------------|---------------------|--------------|
| non_medical_mvp_candidate | 107 | No (pending validation) | Yes | No |
| medical_sensitive_review | 535 | No | Yes | Yes |
| weak_behavioral_or_low_evidence | 30 | No | Yes | Yes |
| no_snp_or_not_testable | 24 | No | No | Yes |
| unclear_manual_review | 0 | No | No | Yes |
| **Total** | **696** | | | |
